In particular, a progressive decrease in the CD3+CD4+ and CD3+CD8+ T cell count, with the lowest levels at month 15 after therapy with oral CLAD, was found in 18 RR-MS patients [27]. The gene discussed is CD8A; the disease is myeloid sarcoma.